TSC2 and neoplasm: The AMPECT trial (6) evaluated the significant anti-tumor activity of nab-sirolimus in patients with advanced or metastatic malignant PEComa carrying mutations in the TSC1/TSC2 genes or activation of the mTOR pathway.